Table 1

Baseline demographic and cyst characteristics on initial imaging in Fukuoka-negative and Fukuoka-positive groups

CharacteristicFukuoka negative* (n=802)Fukuoka positive* (n=299)Total (N=1101)p Value
Female sex477 (59.5)147 (49.2)624 (56.7)0.002
Age, mean (SD), years65.8 (12.9)65.6 (14.3)65.7 (13.3)0.74
Race<0.001
 White737 (91.9)248 (83.5)985 (89.6)
 Caucasian28 (3.5)12 (4.1)40 (3.6)
 Unknown37 (4.6)37 (12.5)74 (6.7)
Type of imaging0.03
 CT570 (71.1)205 (68.6)775 (70.4)
 MRI/MRCP79 (9.9)19 (6.4)98 (8.9)
 EUS153 (19.1)75 (25.1)228 (20.7)
Indication for initial imaging study<0.001
 Abdominal pain158 (19.7)64 (21.4)222 (20.2)
 Jaundice9 (1.1)8 (2.7)17 (1.5)
 Pancreatitis23 (2.9)32 (10.7)55 (5.0)
 Other592 (73.8)186 (62.2)778 (70.7)
 Unknown20 (2.5)9 (3.0)29 (2.6)
Cyst diagnosis<0.001
 Suspected branched duct—IPMN97 (12.1)49 (16.4)146 (13.3)
 Suspected main duct—IPMN0 (0.0)18 (6.0)18 (1.6)
 Suspected mixed—IPMN0 (0.0)30 (10.0)30 (2.7)
 Presumed branched duct—IPMN705 (87.9)202 (67.6)907 (82.4)
No. of cysts0.04
 1558 (69.6)211 (70.6)769 (69.8)
 2108 (13.5)26 (8.7)134 (12.2)
 335 (4.4)8 (2.7)43 (3.9)
 46 (0.7)3 (1.0)9 (0.8)
 ≥595 (11.8)51 (17.1)146 (13.3)
Location of cyst in pancreas†<0.001
 Head298 (37.2)152 (53.0)450 (41.3)
 Neck88 (11.0)23 (8.0)111 (10.2)
 Body228 (28.4)49 (17.1)277 (25.4)
 Tail188 (23.4)63 (22.0)251 (23.0)
Size of largest cyst (mm)†<0.001
 Median (range)10 (0.0–29.0)28.3 (0.0–130.0)11 (0.0–130.0)
Cyst size group† (cm)<0.001
 <1395 (49.3)9 (13.5)434 (39.8)
 1 to <2319 (39.8)55 (19.0)374 (34.3)
 2 to <388 (11.0)57 (19.7)145 (13.3)
 ≥30 (0.0)138 (47.8)138 (12.6)
Family history of pancreatic cancer0.13
 Yes34 (4.2)19 (6.4)53 (4.8)
 No753 (93.9)278 (93.0)1031 (93.6)
 Unknown15 (1.9)2 (0.7)17 (1.5)
Follow-up, years, median (range)4.9 (0.5–16.5)2.2 (0.0–15.6)4.2 (0.0–16.5)<0.001
  • *Values are presented as number and percentage of patients unless specified otherwise.

  • †Missing in the Fukuoka-positive group are location of cyst (n=12), size of largest cyst and cyst size group (n=10).

  • EUS, endoscopic ultrasonography; IPMN, intraductal papillary mucinous neoplasm; MRCP, MR cholangiopancreatography.